Replimune (REPL) Accumulated Expenses (2018 - 2026)
Replimune (REPL) posted Accumulated Expenses of $47.5 million for Q1 2026, up 17.72% sequentially from $40.4 million in Q4 2025, and up 3.48% YoY from $45.9 million in Q1 2025.
Replimune (REPL) Accumulated Expenses (2018 - 2026) Analysis & Trends
Replimune has reported Accumulated Expenses for 9 years, with the latest figure at $47.5 million in Q1 2026.
- Quarterly Accumulated Expenses rose 3.48% year-over-year to $47.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $47.5 million (up 3.48% YoY) and the FY2026 annual result came in at $47.5 million, up 3.48% from the prior year.
- Accumulated Expenses improved to $47.5 million in Q1 2026 per REPL's latest filing, from $40.4 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $47.5 million in Q1 2026 and troughed at $12.2 million in Q2 2022.
- A 5-year average of $30.6 million and a median of $31.4 million in 2024 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2023 and 2024: Accumulated Expenses surged 98.58% in 2023, then decreased 0.72% in 2024.
- Over 5 years, Accumulated Expenses stood at $19.2 million in 2022, then surged by 61.22% to $30.9 million in 2023, then advanced by 19.02% to $36.8 million in 2024, then grew by 9.81% to $40.4 million in 2025, then advanced by 17.72% to $47.5 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $47.5 million, $40.4 million, and $42.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Replimune | 1.24 Bn | 1.24 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47.52 Mn |
| Dec 31, 2025 | 40.37 Mn |
| Sep 30, 2025 | 42.45 Mn |
| Jun 30, 2025 | 40.04 Mn |
| Mar 31, 2025 | 45.92 Mn |
| Dec 31, 2024 | 36.76 Mn |
| Sep 30, 2024 | 31.42 Mn |
| Jun 30, 2024 | 30.91 Mn |
| Mar 31, 2024 | 33.98 Mn |
| Dec 31, 2023 | 30.89 Mn |
| Sep 30, 2023 | 31.65 Mn |
| Jun 30, 2023 | 23.56 Mn |
| Mar 31, 2023 | 24.70 Mn |
| Dec 31, 2022 | 19.16 Mn |
| Sep 30, 2022 | 15.94 Mn |
| Jun 30, 2022 | 12.22 Mn |
| Mar 31, 2022 | 13.39 Mn |
| Dec 31, 2021 | 10.75 Mn |
| Sep 30, 2021 | 9.99 Mn |
| Jun 30, 2021 | 9.19 Mn |